Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: Clues for assessing potential for cardiotoxicity

Journal of Medicinal Chemistry

Volumn 55, Issue 19, 2012, Pages 8260-8271

  Hoffmann, Brian R ^a   El Mansy, Mohamed F ^b   Sem, Daniel S ^b,c   Greene, Andrew S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Marquette University   (United States)

^c Department of Pharmaceutical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; OXIDOREDUCTASE;

AFFINITY CHROMATOGRAPHY; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; ELUTION; GLUCOSE HOMEOSTASIS; HEART ARRHYTHMIA; MITOCHONDRIAL ENERGY TRANSFER; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL EDEMA; PROTEOMICS; RAT; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; CHROMATOGRAPHY, AFFINITY; GLUCONEOGENESIS; GLYCOLYSIS; HYPOGLYCEMIC AGENTS; ION CHANNELS; LIPID METABOLISM; MITOCHONDRIA; MYOCARDIUM; OXIDOREDUCTASES; PROTEIN BINDING; PROTEOME; PROTEOMICS; RATS; SYNAPTIC TRANSMISSION; THIAZOLIDINEDIONES;

EID: 84867362613     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301204r     Document Type: Article

References (53)

1. Smith, M. T. Mechanisms of troglitazone hepatotoxicity Chem. Res. Toxicol. 2003, 16 (6) 679-687
2. Beiderbeck, A. B.; Sakaguchi, M. Commentary on "case series of liver failure associated with rosiglitazone and pioglitazone" by James Floyd et al Pharmacoepidemiol. Drug Saf. 2009, 18 (12) 1247-1249
3. Osei, S. Y.; Koro, C. E.; Cobitz, A. R.; Kolatkar, N. S.; Stender, M. Commentary on "Case series of liver failure associated with rosiglitazone and pioglitazone" by Floyd et al Pharmacoepidemiol. Drug Saf. 2009, 18 (12) 1244-1246
4. Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T. P.; Rastinejad, F. Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA Nature 2008, 456 (7220) 350-356
5. Forman, B. M.; Tontonoz, P.; Chen, J.; Brun, R. P.; Spiegelman, B. M.; Evans, R. M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 1995, 83 (5) 803-812
6. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 1995, 270 (22) 12953-12956
7. Young, P. W.; Buckle, D. R.; Cantello, B. C.; Chapman, H.; Clapham, J. C.; Coyle, P. J.; Haigh, D.; Hindley, R. M.; Holder, J. C.; Kallender, H.; Latter, A. J.; Lawrie, K. W.; Mossakowska, D.; Murphy, G. J.; Roxbee Cox, L.; Smith, S. A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma J. Pharmacol. Exp. Ther. 1998, 284 (2) 751-759
8. Berlie, H. D.; Kalus, J. S.; Jaber, L. A. Thiazolidinediones and the risk of edema: a meta-analysis Diabetes Res. Clin. Pract. 2007, 76 (2) 279-289
9. Cekmen, N.; Cesur, M.; Cetinbas, R.; Bedel, P.; Erdemli, O. Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus J. Intensive Care Med. 2006, 21 (1) 47-50
10. Nissen, S. E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 2007, 356 (24) 2457-2471
11. Graham, D. J.; Ouellet-Hellstrom, R.; MaCurdy, T. E.; Ali, F.; Sholley, C.; Worrall, C.; Kelman, J. A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA, J. Am. Med. Assoc. 2010, 304 (4) 411-418
12. Loke, Y. K.; Kwok, C. S.; Singh, S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 2011, 342, d1309
13. Nesto, R. W.; Bell, D.; Bonow, R. O.; Fonseca, V.; Grundy, S. M.; Horton, E. S.; Le Winter, M.; Porte, D.; Semenkovich, C. F.; Smith, S.; Young, L. H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 2004, 27 (1) 256-263
14. Diamond, G. A.; Kaul, S. Rosiglitazone and cardiovascular risk N. Engl. J. Med. 2007, 357 (9) 938-939; author reply 939-940
15. Wertz, D. A.; Chang, C. L.; Sarawate, C. A.; Willey, V. J.; Cziraky, M. J.; Bohn, R. L. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population Circ. Cardiovasc. Qual Outcomes 2010, 3 (5) 538-545
16. Diamond, G. A.; Bax, L.; Kaul, S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Ann. Intern. Med. 2007, 147 (8) 578-581
17. Ge, X.; Wakim, B.; Sem, D. S. Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins J. Med. Chem. 2008, 51 (15) 4571-4580
18. Feinstein, D. L.; Spagnolo, A.; Akar, C.; Weinberg, G.; Murphy, P.; Gavrilyuk, V.; Dello Russo, C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 2005, 70 (2) 177-188
19. Liu, Y.; Park, F.; Pietrusz, J. L.; Jia, G.; Singh, R. J.; Netzel, B. C.; Liang, M. Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis Physiol. Genomics 2008, 32 (3) 343-351
20. Saraogi, P.; Pillai, K. K.; Singh, B. K.; Dubey, K. Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats. Biomed. Pharmacother. 2010, DOI: 10.1016/j.biopha.2010.12.012.
21. Hancox, J. C. Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone Br. J. Pharmacol. 2011, 163 (3) 496-498
22. Heo, K. S.; Ryoo, S. W.; Kim, L.; Nam, M.; Baek, S. T.; Lee, H.; Lee, A. R.; Park, S. K.; Park, Y.; Myung, C. S.; Kim, D. U.; Hoe, K. L. Cl- -channel is essential for LDL-induced cell proliferation via the activation of Erk1/2 and PI3k/Akt and the upregulation of Egr-1 in human aortic smooth muscle cells Mol. Cell 2008, 26 (5) 468-473
23. Lu, L.; Reiter, M. J.; Xu, Y.; Chicco, A.; Greyson, C. R.; Schwartz, G. G. Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs Diabetologia 2008, 51 (4) 675-685
24. Nakajima, T.; Iwasawa, K.; Oonuma, H.; Imuta, H.; Hazama, H.; Asano, M.; Morita, T.; Nakamura, F.; Suzuki, J.; Suzuki, S.; Kawakami, Y.; Omata, M.; Okuda, Y. Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes Circulation 1999, 99 (22) 2942-2950
25. Szentandrassy, N.; Harmati, G.; Barandi, L.; Simko, J.; Horvath, B.; Magyar, J.; Banyasz, T.; Lorincz, I.; Szebeni, A.; Kecskemeti, V.; Nanasi, P. P. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells Br. J. Pharmacol. 2011, 163 (3) 499-509
26. Zhang, F.; Sowers, J. R.; Ram, J. L.; Standley, P. R.; Peuler, J. D. Effects of pioglitazone on calcium channels in vascular smooth muscle Hypertension 1994, 24 (2) 170-175
27. Halligan, B. D.; Greene, A. S. Visualize: a free and open source multifunction tool for proteomics data analysis Proteomics 2011, 11 (6) 1058-1063
28. Su, A. I.; Cooke, M. P.; Ching, K. A.; Hakak, Y.; Walker, J. R.; Wiltshire, T.; Orth, A. P.; Vega, R. G.; Sapinoso, L. M.; Moqrich, A.; Patapoutian, A.; Hampton, G. M.; Schultz, P. G.; Hogenesch, J. B. Large-scale analysis of the human and mouse transcriptomes Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (7) 4465-4470
29. Su, A. I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K. A.; Block, D.; Zhang, J.; Soden, R.; Hayakawa, M.; Kreiman, G.; Cooke, M. P.; Walker, J. R.; Hogenesch, J. B. A gene atlas of the mouse and human protein-encoding transcriptomes Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (16) 6062-6067
30. Walker, J. R.; Su, A. I.; Self, D. W.; Hogenesch, J. B.; Lapp, H.; Maier, R.; Hoyer, D.; Bilbe, G. Applications of a rat multiple tissue gene expression data set Genome Res. 2004, 14 (4) 742-749
31. Horike, N.; Takemori, H.; Katoh, Y.; Doi, J.; Min, L.; Asano, T.; Sun, X. J.; Yamamoto, H.; Kasayama, S.; Muraoka, M.; Nonaka, Y.; Okamoto, M. Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2 J. Biol. Chem. 2003, 278 (20) 18440-18447
32. Du, J.; Chen, Q.; Takemori, H.; Xu, H. SIK2 can be activated by deprivation of nutrition and it inhibits expression of lipogenic genes in adipocytes Obesity 2008, 16 (3) 531-538
33. Li, Y. T.; Li, L.; Chen, J.; Hu, T. C.; Huang, J.; Guo, Y. W.; Jiang, H. L.; Shen, X. 7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation Acta Pharmacol. Sin. 2009, 30 (9) 1351-1358
34. Higashi, Y.; Holder, K.; Delafontaine, P. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway J. Biol. Chem. 2010, 285 (47) 36361-36368
35. Lea, M. A.; Sura, M.; Desbordes, C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists Anticancer Res. 2004, 24 (5A) 2765-2771
36. Dello Russo, C.; Gavrilyuk, V.; Weinberg, G.; Almeida, A.; Bolanos, J. P.; Palmer, J.; Pelligrino, D.; Galea, E.; Feinstein, D. L. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes J. Biol. Chem. 2003, 278 (8) 5828-5836
37. Brunmair, B.; Staniek, K.; Gras, F.; Scharf, N.; Althaym, A.; Clara, R.; Roden, M.; Gnaiger, E.; Nohl, H.; Waldhausl, W.; Furnsinn, C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004, 53 (4) 1052-1059
38. Scatena, R.; Bottoni, P.; Martorana, G. E.; Ferrari, F.; De Sole, P.; Rossi, C.; Giardina, B. Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications Biochem. Biophys. Res. Commun. 2004, 319 (3) 967-973
39. Das, A. M. Regulation of mitochondrial ATP synthase activity in human myocardium Clin. Sci. 1998, 94 (5) 499-504
40. Sperl, W.; Jesina, P.; Zeman, J.; Mayr, J. A.; Demeirleir, L.; VanCoster, R.; Pickova, A.; Hansikova, H.; Houst'kova, H.; Krejcik, Z.; Koch, J.; Smet, J.; Muss, W.; Holme, E.; Houstek, J. Deficiency of mitochondrial ATP synthase of nuclear genetic origin Neuromuscular Disord. 2006, 16 (12) 821-829
41. Perez-Ortiz, J. M.; Tranque, P.; Burgos, M.; Vaquero, C. F.; Llopis, J. Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: modulation of cytotoxicity by nitric oxide Mol. Pharmacol. 2007, 72 (2) 407-417
42. Schoenmakers, E.; Agostini, M.; Mitchell, C.; Schoenmakers, N.; Papp, L.; Rajanayagam, O.; Padidela, R.; Ceron-Gutierrez, L.; Doffinger, R.; Prevosto, C.; Luan, J.; Montano, S.; Lu, J.; Castanet, M.; Clemons, N.; Groeneveld, M.; Castets, P.; Karbaschi, M.; Aitken, S.; Dixon, A.; Williams, J.; Campi, I.; Blount, M.; Burton, H.; Muntoni, F.; O'Donovan, D.; Dean, A.; Warren, A.; Brierley, C.; Baguley, D.; Guicheney, P.; Fitzgerald, R.; Coles, A.; Gaston, H.; Todd, P.; Holmgren, A.; Khanna, K. K.; Cooke, M.; Semple, R.; Halsall, D.; Wareham, N.; Schwabe, J.; Grasso, L.; Beck-Peccoz, P.; Ogunko, A.; Dattani, M.; Gurnell, M.; Chatterjee, K. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans J. Clin. Invest. 2010, 120 (12) 4220-4235
43. Heppner, T. J.; Bonev, A. D.; Eckman, D. M.; Gomez, M. F.; Petkov, G. V.; Nelson, M. T. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries Pharmacology 2005, 73 (1) 15-22
44. Knock, G. A.; Mishra, S. K.; Aaronson, P. I. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes Eur. J. Pharmacol. 1999, 368 (1) 103-109
45. 2+ mobilization and cell proliferation in vascular smooth muscle cells Br. J. Pharmacol. 1999, 128 (3) 673-683
46. Rusinova, R.; Herold, K. F.; Sanford, R. L.; Greathouse, D. V.; Hemmings, H. C., Jr.; Andersen, O. S. Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery J. Gen. Physiol. 2011, 138 (2) 249-270
47. Bajwa, P. J.; Lee, J. W.; Straus, D. S.; Lytle, C. Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion Am. J. Physiol.: Gastrointest. Liver Physiol. 2009, 297 (1) G82-G89
48. Jeong, I.; Choi, B. H.; Hahn, S. J. Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation Br. J. Pharmacol. 2011, 163 (3) 510-520
49. Eto, K.; Ohya, Y.; Nakamura, Y.; Abe, I.; Fujishima, M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle Eur. J. Pharmacol. 2001, 423 (1) 1-7
50. Song, J.; Knepper, M. A.; Hu, X.; Verbalis, J. G.; Ecelbarger, C. A. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats J. Pharmacol. Exp. Ther. 2004, 308 (2) 426-433
51. Rabol, R.; Boushel, R.; Almdal, T.; Hansen, C. N.; Ploug, T.; Haugaard, S. B.; Prats, C.; Madsbad, S.; Dela, F. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes Diabetes, Obes. Metab. 2010, 12 (9) 806-814
52. Gutschi, L. M.; Malcolm, J. C.; Favreau, C. M.; Ooi, T. C. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy Ann. Pharmacother. 2006, 40 (9) 1672-1676
53. Hernandez, A. V.; Usmani, A.; Rajamanickam, A.; Moheet, A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials Am. J. Cardiovasc. Drugs 2011, 11 (2) 115-128